• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Modified Pulmonary Surfactant Is a Potent Adjuvant That Stimulates the Mucosal IgA Pr

Mingus

Well-known member
[SIZE=-1] http://www.jimmunol.org/cgi/content/abstract/176/2/1122

The Journal of Immunology
, 2006, 176: 1122-1130.
Copyright ? 2006 by The American Association of Immunologists [/SIZE]
Modified Pulmonary Surfactant Is a Potent Adjuvant That Stimulates the Mucosal IgA Production in Response to the Influenza Virus Antigen<sup>1</sup>

<nobr>Dai Mizuno</nobr>, <nobr>Mikiko Ide-Kurihara</nobr>, <nobr>Tomoko Ichinomiya</nobr>, <nobr>Itsuka Kubo</nobr> and <nobr>Hiroshi Kido<sup>2</sup></nobr> [SIZE=-1] Division of Enzyme Chemistry, Institute for Enzyme Research, University of Tokushima, Tokushima, Japan [/SIZE]
<!-- ABS --> The intranasal administration of influenza hemagglutinin (HA)<sup> </sup>vaccine with Surfacten, a modified pulmonary surfactant free<sup> </sup>of antigenic c-type lectins, as a mucosal adjuvant induced the<sup> </sup>highest protective mucosal immunity in the airway. The intranasal<sup> </sup>immunization of mice with HA vaccine (0.2 ?g)-Surfacten<sup> </sup>(0.2 ?g) selectively induced the neutralizing anti-HA<sup> </sup>IgA, but not IgG, and conferred nearly maximal protection in<sup> </sup>the airway, without inducing a systemic response. In contrast,<sup> </sup>intranasal inoculation of vaccine with 0.2 ?g of the potent<sup> </sup>mucosal adjuvant cholera toxin B* (CT-B*), prepared by adding<sup> </sup>0.2% native CT to the B subunit of CT, induced both anti-HA<sup> </sup>IgA and IgG in the airway and in the serum. The intranasal administration<sup> </sup>of HA vaccine alone induced a limited amount of mucosal IgA<sup> </sup>against influenza virus. Although the s.c. administration of<sup> </sup>HA vaccine prominently induced serum IgG and IgA, Surfacten<sup> </sup>and CT-B* did not enhance their induction, and the concentrations<sup> </sup>of Abs leaking into the airways were insufficient to prevent<sup> </sup>viral multiplication. The intranasal administration of HA-Surfacten<sup> </sup>stimulated the expression of MHC class II, CD40, and CD86 molecules<sup> </sup>in the CD11c-positive cells isolated from the nasal mucosa,<sup> </sup>but not the expression of cells from the lungs or spleens. Lymphocytes<sup> </sup>isolated from the airway mucosa after intranasal HA-Surfacten<sup> </sup>immunization prominently induced TGF-
beta.gif
1 which, compared with<sup> </sup>inoculation without Surfacten, promoted an Ag-specific mucosal<sup> </sup>IgA response. Surfacten alone, however, did not induce TGF-
beta.gif
1.<sup> </sup>Our observations suggest that Surfacten, by mimicking the natural<sup> </sup>surfactant, is an effective mucosal adjuvant in the process<sup> </sup>of airway immunization.
 
Back
Top